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Effect of Long-Term Angiotensin-Converting Enzyme 
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Insulin-Resistance Syndrome
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Summary: Cardiovascular risk factors such as hyperten­
sion, diabetes, and dyslipemia are associated with an im­
paired endothelium-dependent vasodilation. In patients 
with type 2 diabetes mellitus, these risk factors are fre­
quently clustered. We investigated whether long-term 
treatment with the angiotensin-converting enzyme (ACB) 
inhibitor perindopril can improve endothelium-dependent 
vasodilation in this particular group of patients. We se­
lected 10 patients with type 2 diabetes and hypertension 
(age 59.4 ± 3.2 years, body mass-index 29,7 ± 1.5 
kg • m~2, blood pressure 169 ± 6/92 ± 1 mm Hg, total 
cholesterol 6.6 ± 0.3 mM). Using venous occlusion ple­
thysmography, we recorded the increases in forearm 
blood flow (FBF) in response to three vasodilator stimuli: 
(a) 5 min of forearm ischemia, (b) infusion of the endo- 
thelium-dependent vasodilator methacholine (Mch) into 
the brachial artery (0.03, 0.3, and 1.0 |xg/min/l(K) ml), and 
(c) intraarterial infusion of the endothelium-independent 
vasodilator sodium nitroprusside (SNP 0.06, 0.2» 0.6 fig/ 
min/100 ml). This procedure was repeated after 6 months
of treatment with perindopril 4-8 mg/day. Forearm vas­
cular resistance (FVR) was calculated by the quotient of 
the mean arterial pressure (MAP) and the FBF. Perin­
dopril reduced blood pressure (BP) by 19/10 mm Hg (p < 
0.05) and increased baseline FVR, but improved neither 
the maximal percentage decrease in vascular resistance 
induced by Mch {from -80 ± 2 to -82 * 2C< ) nor that 
induced by SNP (from -73 t 3 to - 72 -* 3'r). Perin­
dopril decreased the FVR reached after the ischemic 
stimulus from 6.5 ± 1.2 to 4.8 0.6 U (p < 0,05). Six 
months of treatment with perindopril improved neither 
the endothelium-dependent nor endothelium-independent 
vasodilation, but significantly reduced minimal FVR (p < 
0.05). These observations suggest a reduction of struc­
tural vascular changes after long-term AO'H inhibition. 
Key Words; Endothelium-dependent vasodilation— 
Angiotensin-converting enzyme inhibition— Forearm blood 
How—Insulin resistance—Diabetes—Hypertension—Ple­
thysmography—Perindopril.
The clustering of type 2 diabetes mellitus, hyper­
tension, and dyslipemia has been described as the 
“ insulin resistance (IR) syndrome,” “ Reaven’s 
syndrome,” or “syndrome X ” (1). All components 
of this syndrome have been associated with an im­
paired endothelium-dependent vascular relaxation. 
In animal models, this was shown by Bucala and 
colleagues (2) and Tesfamariam and co-workers (3) 
for diabetes, by Tesfamariam and Halpern (4) and 
Boegehold (5) for hypertension, and by Osborne 
and colleagues (6) and Shimokawa and Vanhoutte 
(7) for hypercholesterolemia. Although human in
vivo data on endothelium-dependent vasorelaxation 
are scarce, an impairment of endothelium-depen­
dent vascular relaxation has repeatedly, though not 
consistently, been shown for hypertension (8-10) 
and hypercholesterolemia (11). as well as for type 2 
diabetes (12). Consequently, thi’ IR syndrome could 
be accompanied by an impaired endothelium- 
dependent vascular relaxation.
Besides decreasing blood pressure (BP), an­
giotensin converting enzyme (ACH) inhibitors have 
been reported to improve endothelium-dependent 
vasodilation and structural changes in the vascular
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wall in animal models (13,14) as well as in humans 
(15,16). However, no human data are yet available 
regarding the effect of ACE inhibitors on endothe­
lium-dependent vasodilation in hypertensive, type 2 
diabetic patients. An improvement in an impaired 
endothelium-dependent vasodilation could be of 
clinical importance in the management of patients 
with the IR syndrome.
To address this hypothesis, we assessed the endo­
thelium-dependent forearm vasodilator response to 
infusion of the muscarinic receptor agonist metha- 
choline (Mch) into the brachial artery (11), and the 
endothelium-independent vasodilator response to 
intraarterial infusion of sodium nitroprusside 
(SNP). To measure long-term effects of ACE inhi­
bition, we performed experiments in exactly the 
same way before as well as after 6 months of ACE 
inhibition.
METHODS 
Patients
After the study protocol was approved by the local 
ethics committee, 10 patients with type 2 diabetes melli- 
tus with a duration of at least 4 years and a repeatedly 
measured BP of at least 140/90 mm Hg after 15 min of 
supine rest (measured by Critikon Dinamap device, type 
1846 SX/P), were selected. Subjects with impaired renal 
function (plasma creatinine >130 ixM), orthostatic hy­
potension [a decrease in systolic BP (SBP) after standing 
up of >20 mm Hg)], or treatment with anticoagulant or 
nonsteroidal antiinflammatory drugs were excluded from 
the protocol. The use of antihypertensive and/or hypo­
glycemic drugs before selection was not an exclusion cri­
terion, but such medication could not be changed during 
the period of the trial. The use of ACE inhibitors ^6 
months before the first test was an exclusion criterion.
Protocol
All subjects participated in two tests from 1330 to 1730 
h, one before and one during treatment with the ACE 
inhibitor perindopril. These tests were performed in a 
quiet, temperature-controlled (22°C) room to ensure that 
FBF recordings predominantly referred to forearm mus­
cle perfusion and to exclude FBF fluctuations due to 
changes in temperature (17). All participants were asked 
to abstain from alcohol and caffeine or smoking for at 
least 24 h before the test. The patients receiving oral hy­
poglycemic therapy were asked not to use those drugs 
from 24 h before the test until the end of the test. The 
eventual remaining medication was continued. Subjects 
receiving insulin had their regular subcutaneous morning 
dose. All subjects were asked to have their usual break­
fast but not to eat for at least 2 h before the test was 
performed.
After forearm volume (FAV) was measured by water 
displacement, the subjects remained in the supine posi­
tion. Under local anesthesia, the left antecubital brachial 
artery was cannulated with a 20-gauge Angiocath (De­
seret Medical, Beckton Dickinson, Sandy, UT, U.S.A.) 
for intraarterial drug infusion with an automated syringe 
infusion pump (type STC-521, Terumo, Tokyo, Japan) as 
well as for BP and heart rate (HR) monitoring (type 
78353B, Hewlett-Packard GmbH, Boblingen, Germany).
Plasma glucose levels were monitored during the tests at 
half-hour intervals (Accutrend, type 1284851, Boe- 
hringer, Mannheim, Germany) and, if necessary, correc­
tions were made by infusing glucose 5% or insulin intra­
venously in the contralateral arm.
FBF recordings were started after a 45-min equilibra­
tion period. We measured FBF at both forearms by ECG- 
triggered venous occlusion mercury-in-silastic strain- 
gauge plethysmography (Hokanson EC4, D. E. Hokan- 
son, Washington). To ensure that FBF recordings 
referred only to the forearm skeletal muscle circulation, 
the hand circulation was occluded during recordings by a 
wrist cuff inflated 100 mm Hg above the SBP (18).
We investigated vasodilator responses to three differ­
ent stimuli. Each of these stimuli was preceded by 5 min 
of intraarterial infusion of placebo, during which baseline 
values of all parameters were recorded. First we assessed 
structural changes in the vascular wall by measuring the 
postocclusive reactive hyperemic (PORH) response of 
the forearm vascular bed to 5 min of forearm ischemia 
(19) while infusing placebo, achieving this by inflating a 
cuff around the upper arm to 100 mm Hg above the SBP, 
This response is considered a measure of the maximal 
vasodilator capacity, which indicates structural changes 
in the vessel wall on arteriolar and lower level (19).
Fifteen minutes later, new baseline recordings were ob­
tained; subsequently endothelium-dependent vasodilator 
responses to intraarterial infusion of Mch were recorded. 
Three increasing dosages of Mch were given (0.03, 0.3, 
and 1.0 fxg/min/100 ml FAV, 5 min/dose). Forty-five min­
utes later, we obtained new baseline recordings and then 
recorded the vasodilator responses to intraarterial infu­
sion of three increasing dosages of SNP (0.06, 0.2, and 0.6 
|xg/min/100 ml FAV, 5 min/dose). This procedure was 
repeated in exactly the same way after 6 months of treat­
ment with perindopril 4-8 mg/day. During these 6 
months, preexisting concomitant medication was not al­
tered, and the patients made a monthly control visit to the 
outpatient clinic. Moreover, blood samples were taken to 
monitor possible side effects. The dosage of perindopril 
was increased from 4 to 8 mg/day unless BP decreased 
>20 mm Hg or had decreased to <120/80 mm Hg.
Drugs
Mch was prepared freshly for each experiment by our 
pharmaceutical laboratory in a solution in NaCl 0.9%. 
SNP was purchased from Hoffmann La Roche 
(Mijdrecht, The Netherlands). Protected from light, it 
was dissolved in 5% glucose just before administration. 
Saline 0.9% was used as placebo in the baseline record­
ings and the PORH test, except for the baseline record­
ings preceding the SNP test, for which 5% glucose was 
used. All infusions were administered at a rate of 100 
|xl/min/l00 ml FAV.
Statistics and calculations
Each drug and each dosage was administered for 5 min, 
during which time all relevant registrations were made. 
Each minute, three FBF curves were recorded. For the 
calculations of the baseline FBF, all recorded curves 
were used. For the PORH response, only the highest FBF 
was used. The mean FBF values for each dosage of Mch 
and SNP were calculated by averaging the values from 
the last 2 min per dosage, when a steady state was 
achieved. The FBF ratio was calculated as the quotient of
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the FBF from the experimental and nonexperimental side 
(8,20). Absolute and percentage changes for each stimu­
lus were calculated from the preceding baseline value. 
The FVR was calculated by the quotient of the mean 
arterial pressure (MAP) and the FBF.
Differences in baseline levels and responses to ische­
mia before and after treatment with perindopril were eval­
uated by a paired Student’s t test. The vasodilator re­
sponses to the various drugs and dosages were compared 
by a multivariate analysis of variance (MANOVA) with 
repeated measures, Differences were considered statisti­
cally significant at p < 0.05. All results are mean values ± 
SE, unless indicated otherwise,
RESULTS
Subj ects
Three male and 7 female patients with a mean age 
of 59.4 ± 3.2 years gave their informed consent. 
The average weight was 82,7 ± 5.8 kg, and the 
mean body mass index was 29.7 ± 1.5 kg/m“. The 
FAV averaged 1,031 ± 80 ml. The mean duration of 
diabetes was 11.1 ± 2.3 years, that of hypertension 
was 11.3 ± 3.4 years, and mean fasting blood glu­
cose was 12.2 ± 1.5 mM. The average glycosylated 
hemoglobin was 8.7 ± 0,5%, with reference values 
of 4.2-6.3%. Fasting insulin concentration averaged 
19.7 ±3. 7  mU/L (reference values 8-20 mU/L), 
Diabetes was controlled by diet and oral hypogly­
cemic drugs in 5 patients, 4 patients used subcuta­
neous insulin preparations, and 1 patient was not 
treated with either diet or medication. Four patients 
had an increased albumin excretion ratio (>20 fig/ 
min), 4 patients had diabetic retinopathy, and 5 had 
decreased vibration perception. Five patients were 
already receiving antihypertensive drug therapy; 
used (3-blockers (3) and thiazide diuretics (2); 1 also 
was treated with nitrates and I with a calcium an­
tagonist, but none were receiving ACE inhibitors.
Effects of ACE inhibition on baseline parameters
Table 1 and Fig. 1 show the baseline characteris­
tics of the patients before and after 6 months of 
treatment with 4-8 mg of the ACE inhibitor perin­
dopril. Perindopril significantly reduced the base­
line BP from 169.4 ± 5.9/92.6 ± 1.2 to 150.0 ± 
4,3/83.0 ±3.1 mm Hg, as measured by Dinamap
vv rvR
TABLE 1.
Parameter Before
« » n ta >^ . . . . . M| ... ( (
p-Value After
HbAlc (%) «.7 ± I .fi 0.60 8.6 - 1.7
AER (|ig/min) 17.5 ± 11.3 0.03 9.5 ± 5.3
Great (jxAÌ) 77.9 ± 12.1 0.95 78.0 t  15.4
K* (mM) 4.4 ± 0.3 0.87 4.4 ± 0.4
Glue (mA/) 12.2 ± 3.1 0.29 11.0 3.3
Ins (U/L) 19.7 ± 13.6 0.60 19.0 ± 12.6
Gluc/ins (mmol/Uj 0.76 ± 0.53 0.07 0.65 ± (1.45
ValuevS are means ± SD; p-values derived from paired Student\ / rest. 
HbAlc, glycosylated hemoglobin; AER, albumin excretion ratio; t'real, 
serum creatinine concentration; K ", serum potassium concentration; 
Glue, plasma glucose concentration; Ins, plasma insulin concentration; 
Gluc/ins, quotient of glucose and insulin plasma concentrations.
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FIG. 1. The baseline individual and mean ( ■* SE) values of the 
pulse pressure (PP), the forearm vascular resistance (FVR), 
the mean arterial pressure (MAP), and the heart rate (HR) 
before and afterS months of angiotensin-converting enzyme 
inhibition by perindopril, with indication of p-values from 
paired Student's f tests.
device (p <  0.05) and from 174*6 ± 7.1/80,8 ± 2,2 to 
145.6 ± 6.3/75.8 ± 2,7 mm Hg as measured intraar- 
terially (p < 0.05),
The baseline pulse pressure was significantly re­
duced (p < 0.01). The baseline HR tended to be 
lower after 6 months of treatment (p - 0.08), After 
6 months of ACE inhibition, the baseline FBF was 
significantly lower at the experimental left side (p < 
0.05) while the FBF ratio remained unchanged. 
Moreover, the baseline FVR before treatment was 
significantly increased by the perindopril treatment 
(p < 0.05) (Fig. 1).
Table 1 shows that fasting plasma glucose con­
centrations showed no significant changes during 
the 6 months of treatment. This absence of changes 
also accounts for HbA lc and fasting insulin concen­
trations. During treatment, plasma cholesterol de­
creased from 6,62 ± 0.35 to 6,31 * 0.34 in A/ (p - 
0.13), triglycerides decreased from 2.74 * 0.65 to 
2,25 :t 0.56 mM  (p - 0.05), high density lipoprotein
cholesterol increased from 1.14 *: 0.08 to 1.23 ± 
0,07 a\M (p - 0,07), and low density lipoprotein 
cholesterol increased from 4.17 »; 0,30 to 4.38 ± 
0,29 mM (p -  0.58). Moreover, albumin excretion 
ratio decreased significantly during 6 months of 
ACE inhibition (p < 0.05).
In only 1 patient w*as it necessary to increase the 
perindopril dosage from 4 to 8 nig/day to achieve an 
adequate BP reduction. One patient developed a 
cough during treatment, but was able to continue 
the medication. There were no other side effects.
Effects of ACE inhibition on the forearm 
vasodilator responses to the three stimuli
Table 2 and Fig. 2 show the absolute values for 
FBF and FVR; Fig. 3 shows the percentage of dec­
rement from baseline in FVR.
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TABLE 2. Mean (^SE) of the hemodynamic 
parameters throughout the test before as well as after
treatment with perindopril
Condition
MAP 
(mm Hg)
FBF(L) 
(ml/100 ml 
FAV/min)
FBF ratio
(UR)
Before
Placebo 117.5 ± 2.5 3.5 + 0.5 1.3 11 0.1
PORH 111.8 ± 4.4 19.7 H- 2.2
Placebo 119.8 4- 3.6 3.3 0.4 1.2 -t- 0.1
Mch 0.03 116.8 ± 3.7 6.7 ± 0.8 2.4 0.2
Mch 0.3 117.5 ± 3.8 13.1 ± 1.4 5.3 'jr 0.6
Mch 1.0 116.9 ± 3.7 17.9 ± 1.8 8.5 ± 1.7
Placebo 123.2 ± 3.7 3.5 ± 0.5 1.3 ± 0.1
SNP 0.06 122.4 3.8 5.1 it 0.8 1.9 ± 0.2
SNP 0.2 120.1 ± 3.7 8.0 ± 1.1 3.3 0.4
SNP 0.6 117.8 + 3.6 14.0 4"*•*» 2.5 5.7 1.2
After
Placebo 105.6 3.5" 2.5 ± 0.3* 1.0 0.1
PORH 102.6
» 3.6 22.4 ± 2. l fl
Placebo 112.0 db 6.4 2.6 ir 0.4° 1.0 0.1
Mch 0.03 111.9 ± 4.0 5.0 -f* 0.7 2.2 ± 0.2
Mch 0.3 109.8 ± 3.3 12.4, + 2.3 5.0 0.7
Mch 1.0 110.4 3.5 16.4 it 3.1 7.0 ± 0.8
Placebo 118.9 i 4.0 2.5 0.3° 1.1 ± 0.1
SNP 0.06 117.8 3.1 4.9 0.6 2.3 Hh 0.3
SNP 0.2 118.2 3.5 7.7 zt 1.0 3.4 0.5
SNP 0.6 117.2 ± 3.6 10.4 -h 1.7 4.9 ± 0.8
PORH, postocclusive reactive hyperemia; MAP, mean arterial 
pressure; FBF, forearm blood flow; Mch, methacholine; SNP, 
sodium nitroprusside; MAP, mean arterial pressure; FBF(L), 
forearm blood flow at the experimental side; FBF (L/R), the ratio 
of the FBF at the experimental and nonexperimental side, before 
and after treatment with perindopril.
Baseline values are shown as placebo. Responses to three 
stimuli are shown: (a) PORH, 5-min forearm ischemia; (b) Mch
0.03, 0.3, and 1.0, three increasing dosages of methacholine; and 
(c) SNP 0.06, 0.2, and 0,6, three increasing dosages of sodium 
nitroprusside.
“ p < 0.05 versus before perindopril, paired t test.
PORH
The maximum FBF in response to 5-min forearm 
ischemia was significantly greater after treatment (p 
< 0.01). The absolute response in FBF from base­
line increased with treatment (16.2 ± 2.1 vs. 19.9 ± 
1.9 ml/100 ml/min, p < 0.01), as did the percentage 
response of FBF from baseline to ischemia (515 ± 
80% before and 918 ± 154% after treatment, p < 
0 .01).
The minimal FVR during PORH was decreased 
after treatment with perindopril (6.5± 1.2 vs. 4.8 ± 
0.6 AU, p <  0.05). The absolute decrease in FVR 
from baseline was greater after treatment (-32.7 ± 
3.7 vs. -47.3 ± 7.8 AU, p < 0.05), as was the 
percentage decrease from baseline in FVR ( “-*82.7 
± 2.7% without and -89.5 ± 1.3% with perin­
dopril, p < 0.01),
Endothelium-dependent vasorelaxation
Perindopril did not change either the increase in 
FBF significantly during the three dosages of Mch, 
or the absolute responses from baseline or the per-
FIG. 2. The mean (± SE) of the forearm vascular resistance 
during the three different vasodilator stimuli (PL, baseline; 
PORH, postocclusive reactive hyperemia; M1, 2, and 3, three 
dosages of methacholine; S1, 2, and 3, three dosages of so­
dium nitroprusside), before and after 6 months of angioten­
sin-converting enzyme inhibition. ^Statistically significant 
differences versus before treatment with perindopril (p < 
0.05).
centage increases (Table 2 and Fig. 2). The minimal 
FVR during Mch infusions was not significantly al­
tered by 6 months of ACE inhibition (7.8 ±1.5 
before 9.4 ±1.7 AU after treatment). However, 
absolute decrements in FVR in response to Mch 
were significantly greater after perindopril (p < 
0.05), but the percentage changes in FVR from 
baseline were not. Neither did the absolute values 
of FBF ratio, absolute responses from baseline, or 
the percentage responses to Mch from baseline of 
FBF ratio change significantly with long-term ACE 
inhibition.
Endothelium-independent vasorelaxation
Before and after 6 months of perindopril treat­
ment (Table 2 and Fig. 2), the three dosages of SNP
Oi
- 20 -
-40 J
- 60 -
-80-
- 100-
Before Perindopril 
m After Perindopril
PORH Mchl Mch 2 Mch 3 SNP1 SNP2 SNP3
FIG. 3. The percentage of decrease from baseline in forearm 
vascular resistance (FVR) for each vasodilator stimulus 
(PORH, postocclusive reactive hyperemia; Mch 1, 2, and 3, 
three dosages of metacholine; SNP 1,2, and 3, three dosages 
of sodium nitroprusside), before and after treatment with the 
angiotensin-converting enzyme inhibitor. ‘Statistically signif­
icant difference of the maximal decrease in FVR versus be­
fore treatment with perindopril (p < 0.05).
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increased FBF dose dependency to the same ex­
tent. Absolute changes in.FBF from baseline in re­
sponse to SNP infusions were not significantly dif­
ferent after the treatment with perindopril, nor were 
the percentage changes from baseline.
Neither the levels of FVR reached in response to 
the three dosages of SNP nor the absolute nor the 
percentage changes from baseline in FVR were sig­
nificantly altered by 6 months of ACE inhibition. 
The same was true of the values achieved and 
changes from baseline of the FBF ratio.
By relating the changes in FVR during Mch and 
SNP infusion to the maximal vasodilator response 
during PORH, we corrected for changes in baseline 
values, because minimal FVR reached after ische­
mia is independent of baseline values (21). None­
theless, no improvements were noted in either en­
dothelium-dependent or endothelium-independent 
vasodilation.
DISCUSSION
Systemic changes during the experiments
Table 2 shows that there were no significant 
changes in baseline FBF ratio. Before treatment 
with perindopril, baseline FBF ratio ranged from 
1.2 ± 0.1 to 1.3 ± 0.1. After 6-month treatment, 
there was a similar range of 1.0 ± 0.1 to 1.1 ± 0.1. 
Increases in FBF ratio during Mch and SNP infu­
sion were strictly coupled to increases in FBF at the 
experimental side and were certainly not related to 
changes in control arm blood flow, indicating that 
systemic changes could not have influenced the re­
sults.
During the experiments, SBP and diastolic BP 
(DBP) increased significantly (p <  0.05), Before 
treatment, the SBP increased from 174.6 ± 7.1 to 
182.7 ± 6.4 mm Hg. Likewise DBP increased from 
80.8 ± 2.1 mm Hg during the first baseline record­
ing to 87.4 ± 3.1 mm Hg during the third with pla­
cebo. The MAP showed an increase of 5.8 mm Hg 
(p = NS). After 6 months of treatment with perin­
dopril equal and significant increases again oc­
curred in SBP (145.6 ± 6.3-165.8 ± 9.2 mm Hg), 
DBP (75.7 ±2.7-85.1 ± 1.8 mm Hg), and MAP (105 
± 3-118 ± 4 mm Hg) (p < 0.05). The HR showed 
only slight and insignificant alterations throughout 
the experiments.
During the experiments, the plasma glucose con­
centration was monitored. Before treatment the av­
erage plasma glucose level was 13.8 ± 1.3 mM at 
the beginning of the experiments and 10.7 ± 0.8 mM 
at the end, whereas after 6 months of ACE inhibi­
tion these values were 9.8 ± 1.0 and 9.0 ± 0.7 mM. 
At the actual timepoints of FBF measurements, 
plasma glucose concentrations remained within a 
range of 5-15 mM. The average intraindividual 
plasma glucose variation during the tests was 2.9 
mM, with a minimum of 0.7 and a maximum fluc­
tuation of 7.3 mM.
Responses to vasodilator stimuli 
The improvements after 6 months of ACE inhibi­
tion of the absolute and relative responses to ische­
mia (PORH) could be related to an improvement in 
vascular structural changes (19). According to find­
ings in comparable studies, these changes are prob­
ably due to the ACE inhibition and not to BP re­
duction itself (22). Because the minimal vascular 
resistance as reached after ischemia is independent 
of baseline (23), the perindopril-induced decrease in 
baseline FBF cannot account for this improvement. 
For the particular group of patients in our study, the 
minimal FVR was shown to be significantly higher 
as compared with that of a healthy control group 
(24). The decrease in the minimal FVR is therefore
an improvement toward normal. Thus result is in 
accordance with the study of De Cesaris and col­
leagues (16), who suggested that long-term treat­
ment with an ACE inhibitor can induce a regression 
of structural changes in large arteries in patients 
with hypertension. Therefore, our data strongly 
suggest a reduction of structural vascular changes, 
although firm conclusions cannot he drawn because 
our ischemic stimulus is not the optimal stimulus to 
assess minimal vascular resistance (23).
Although there have been contradictory reports 
on endothelium-dependent vasodilation in patients 
with type 1 diabetes mcllitus (25.26), McVeigh and 
co-workers (12) reported impaired endothelium- 
dependent vasodilation in type 2 diabetic patients. 
As compared with healthy volunteers, our study 
population also showed an impaired endothelium- 
dependent vasodilation (24), which is supported by 
data of Creager and associates (II), who also used 
Mch as an endothelium-dependent vasodilator.
ACE inhibitors have been reported to improve 
endothelial function in the animal model (13,14) 
and, at least in the short-term, to improve endothe­
lium-dependent vasodilation in human single-dose 
studies (15,27). In contradiction to our expecta­
tions, 6 months of ACE inhibition with perindopril 4 
mg/day did not improve endothelium-dependent va­
sodilation. Probably this cannot be explained by 
noncompliance of the patients, because other rele­
vant parameters such as BP and albumin excretion 
ratio both were significantly reduced by perin­
dopril. Another theoretical explanation is the ab­
sence of a sulfhydryl group in perindopril. Several 
studies have shown that a sulfhydryl group contrib­
utes significantly to the potentiation of endothe­
lium-dependent vasodilation (28,29). However, it 
has to be emphasized that some of these positive 
results were obtained with ACE inhibitors without a 
sulfhydryl group (16). Recently, Pan/,a and col­
leagues (30) reported that reducing BP caused no 
improvement in endothelium-dependent vasodila­
tion in hypertensive patients. Schit'frin and co­
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workers (22) investigated vascular reactivity and 
structure in subcutaneous gluteal biopsies before 
and after 1 year of treatment of a group of hyper­
tensive patients with either a (3-blocker or an ACE 
inhibitor. Endothelium-dependent vasodilation was 
not improved in either group, but in the ACE- 
inhibited group structural changes were reduced. 
Apparently, potentiation of endothelium-dependent 
vasodilation does not occur after chronic treatment 
with nonsulfhydryl group-containing ACE inhibi­
tors.
Changes in baseline parameters 
Figure 1 shows reductions in the baseline pulse 
pressure, MAP, and the HR, as well as an increase
ot bVR by 6 months of ACE inhibition with perin- 
dopril. These changes can be considered a trend 
toward normalization. High insulin levels have been 
reported lo have vasodilator effects (31). However, 
il is unlikely that insulin played a role in these 
changes since fasting insulin concentrations were 
not altered by 6 months of ACE inhibition, Despite 
the reduced BP, baseline FVR surprisingly was sig­
nificantly greater after treatment. Our results do not 
allow conclusions regarding the mechanisms that 
could explain the combination of BP decrease and 
FVR increase, The changes in the parameters 
shown in Fig. 1 might suggest changes in cardiac 
output or peripheral resistance, but unfortunately 
these were not measured. Furthermore, the mi­
croalbuminuria was significantly reduced. Serum 
creatinine and potassium had not changed during 
the 6 months of ACE inhibition, and there was no 
clinically relevant effect on lipids. Together, these 
findings are indicative of a reduction in cardiovas­
cular risk.
Systemic parameters during the experiments
During the tests, all patients had a slight decrease 
in plasma glucose concentration that occurred be­
fore as well as after 6 months of ACE inhibition in 
an almost identical way. Fasting glucose and insulin 
levels as well as their ratio showed only slight 
changes during the 6 months of treatment. More­
over, HbAlc had not changed during treatment. 
Therefore, we found no arguments for an influence 
of perindopril on glucose metabolism, which is in 
accordance with the literature (32).
All values of plasma glucose concentrations were 
helween 4.4 and 15.1 mM during measurements. 
Furthermore, the average intraindividual plasma 
glucose fluctuation during the tests was very low; 
therefore, it is unlikely that plasma glucose concen­
trations influenced the results.
Table 2 shows that the BP slightly increased dur­
ing the course of the test. This increase in BP oc­
curred during the equilibration period between the 
last dosage of Mch and the third baseline recording. 
We emphasize that these alterations in BP were
similar before and after treatment and therefore 
could not have affected the final results.
Study limitations
The absence of a placebo group and a patient 
control group are limitations of the study. Yet con­
trol gi oups would have been of greater importance 
if perindopril had had significant effects on endo­
thelium-dependent vasodilation.
We conclude that 6 months of ACE inhibition 
with perindopril 4 mg/day did not specifically im­
prove endothelium-dependent vasodilation but im­
proved the hyperemic response to an ischemic stim­
ulus, which may indicate an improvement in struc­
tural changes in the vascular wall.
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